Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 571 AL 585

Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies

Zetterberg H, Bendlin BB.

Mol Psychiatry. 2021 Jan;26(1):296-308. doi: 10.1038/s41380-020-0721-9. Epub 2020 Apr 6.

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

Gavrilova SI, Alvarez A.

Med Res Rev. 2021 Sep;41(5):2775-2803. doi: 10.1002/med.21722. Epub 2020 Aug 17.

Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders

Benfante R, Di Lascio S, Cardani S, Fornasari D.

Aging Clin Exp Res. 2021 Apr;33(4):823-834. doi: 10.1007/s40520-019-01359-4. Epub 2019 Oct 3.

A meta-analysis of peripheral tocopherol levels in age-related cognitive decline and Alzheimer's disease

Ashley S, Bradburn S, Murgatroyd C.

Nutr Neurosci. 2021 Oct;24(10):795-809. doi: 10.1080/1028415X.2019.1681066. Epub 2019 Oct 29.

Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease

Shimura H, Saiko A, Hayashi A, Hattori N, Urabe T.

BMC Neurol. 2021 Feb 10;21(1):61. doi: 10.1186/s12883-021-02098-8.

Melatonin Receptor as a Drug Target for Neuroprotection

Wongprayoon P, Govitrapong P.

Curr Mol Pharmacol. 2021;14(2):150-164. doi: 10.2174/1874467213666200421160835.

Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders

Yadav N, Mittal A, Ali J, Sahoo J.

Curr Protein Pept Sci. 2021;22(6):458-469. doi: 10.2174/1389203721999201111195512.

Cognitive Impairment in Older Adults and Therapeutic Strategies

Montine TJ, Bukhari SA, White LR.

Pharmacol Rev. 2021 Jan;73(1):152-162. doi: 10.1124/pharmrev.120.000031.

Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route

Dali P, Shende P.

Curr Pharm Biotechnol. 2021;22(11):1466-1481. doi: 10.2174/1389201021666201218130947.

Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times

Nabavi SM, Sobarzo-Sánchez E.

Curr Neuropharmacol. 2021;19(2):112-113. doi: 10.2174/1570159X1902201231153120.

The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models

MacDougall G, Brown LY, Kantor B, Chiba-Falek O.

Mol Ther. 2021 Mar 3;29(3):949-972. doi: 10.1016/j.ymthe.2021.01.001. Epub 2021 Jan 9.

GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment

Pal D, Mukherjee S, Song IH, Nimse SB.

Curr Drug Targets. 2021;22(15):1725-1737. doi: 10.2174/1389450122666210114095307.

Deep Brain Stimulation in Alzheimer's Disease: Targeting the Nucleus Basalis of Meynert

Chen YS, Shu K, Kang HC.

J Alzheimers Dis. 2021;80(1):53-70. doi: 10.3233/JAD-201141.

Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders

Saha S, Pal D, Nimse SB.

Curr Drug Targets. 2021;22(12):1437-1462. doi: 10.2174/1389450122666210120143953.

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer's and Parkinson's Disease

Lee JH, Kim HJ, Kim JU, Yook TH, Kim KH, Lee JY, Yang G.

Int J Mol Sci. 2021 Jan 28;22(3):1324. doi: 10.3390/ijms22031324.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias